

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

tezacaftor-ivacaftor; ivacaftor (Symdeko)

Initiation (new start) criteria: Non-formulary **tezacaftor-ivacaftor; ivacaftor (Symdeko)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescriber specializes in the treatment of cystic fibrosis (CF)
- Patient is at least 6 years of age
- Diagnosis of CF confirmed by a clinician with expertise in providing CF care
- Two copies of F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene OR one responsive mutation (see Table 1) in the CFTR gene detected using either an FDA-cleared CF mutation test OR testing was completed by a CLIA certified laboratory.

Criteria for *new members entering Kaiser Permanente already taking the medication who have not been reviewed previously:* Non-formulary **tezacaftor-ivacaftor; ivacaftor (Symdeko)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescriber specializes in the treatment of cystic fibrosis (CF)
- Patient is at least 6 years of age
- Diagnosis of CF confirmed by a clinician with expertise in providing CF care
- Two copies of F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene OR one responsive mutation (see Table 1) in the CFTR gene detected using either an FDA-cleared CF mutation test OR testing was completed by a CLIA certified laboratory.

kp.org

Revised: 01/14/21
Effective: 03/04/21

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

tezacaftor-ivacaftor; ivacaftor (Symdeko)

Table 1: CFTR Gene Mutations Responsive to tezacaftor-ivacaftor; ivacaftor (Symdeko)¹

546insCTA	E92K	G576A;R668C	L967S	R117H	S737F
711+3A→G	E116K	G622D	L997F	R117L	S912L
2789+5G→A	E193K	G970D	L1324P	R117P	S945L
3272-26A→G	E403D	G1069R	L1335P	R170H	S977F
3849+10kbC→T	E588V	G1244E	L1480P	R258G	S1159F
A120T	E822K	G1249R	M152V	R334L	S1159P
A234D	E831X	G1349D	M265R	R334Q	S1251N
A349V	F191V	H939R	M952I	R347H	S1255P
A455E	F311del	H1054D	M952T	R347L	T338I
A554E	F311L	H1375P	P5L	R347P	T1036N
A1006E	F508C	I148T	P67L	R352Q	T1053I
A1067T	F508C;S1251N	I175V	P205S	R352W	V201M
D110E	F575Y	I336K	Q98R	R553Q	V232D
D110H	F1016S	I601F	Q237E	R668C	V562I
D192G	F1052V	I618T	Q237H	R751L	V754M
D443Y	F1074L	I807M	Q359R	R792G	V1153E
D443Y;G576A;R668C	F1099L	I980K	Q1291R	R933G	V1240G
D579G	G126D	I1027T	R31L	R1066H	V1293G
D614G	G178E	I1139V	R74Q	R1070Q	W1282R
D836Y	G178R	I1269N	R74W	R1070W	Y109N
D924N	G194R	I1366N	R74W;D1270N	R1162L	Y161S
D979V	G194V	K1060T	R74W;V201M	R1283M	Y1014C
D1152H	G314E	L15P	R74W;V201M;D1270N	R1283S	Y1032C
D1270N	G551D	L206W	R75Q	S549N	
E56K	G551S	L320V	R117C	S549R	
E60K	G576A	L346P	R117G	S589N	

1. Symdeko [package insert]. Vertex Pharmaceuticals Incorporated; Boston, MA. December 2020.

kp.org

Revised: 01/14/21
Effective: 03/04/21

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest